Resistance to anticancer therapies includes primary resistance, usually related to lack of
target dependency or presence of additional targets, and secondary resistance, mostly …

Despite survival improvements achieved over the last two decades, prostate cancer remains
lethal at the metastatic castration-resistant stage (mCRPC) and new therapeutic approaches …

Background Innovations in imaging and molecular characterisation together with novel
treatment options have improved outcomes in advanced prostate cancer. However, we still …

Preclinical evidence has suggested an interplay between the androgen receptor, which
largely drives the growth of prostate cancer cells, and poly (ADP-ribose) polymerase. This …

Multi-tyrosine kinase inhibitors (MTKIs) have thus far had limited success in the treatment of
castration-resistant prostate cancer (CRPC). Here, we report a phase I–cleared orally …

Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with
an aggressive disease course despite currently approved therapeutics. The recent …

The treatment landscape of metastatic prostate cancer has evolved significantly over the
past two decades. Several landmark phase 3 trials led to new drug approvals and rapid …

The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions
regarding the workup of patients with prostate cancer, risk stratification and management of …

Prostate cancer (PCa) incidence and mortality have rapidly increased in China. Notably,
unique epidemiological characteristics of PCa are found in the Chinese PCa population …

The introduction of second-generation androgen receptor antagonists (SG-ARAs) has
greatly impacted the treatment of metastatic prostate cancer, providing tolerable and …